Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Glycorex Transplantation ABFRA:O33 -31.05%61 Altman Z-Score is 1.40 as of Aug. 05, 2026, which is 87% below its 10-year median of 10.83. GuruFocus rates FRA:O33 with a GF Score™ of 61/100 and a GF Value™ of €0.14 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 932 Biotechnology companies, Glycorex Transplantation AB ranks worse than 52.79% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 2.09 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
Glycorex Transplantation AB has a Altman Z-Score of 1.40, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Glycorex Transplantation AB's Altman Z-Score or its related term are showing as below:
FRA:O33'
s Altman Z-Score Range Over the Past 10 Years
Min: -1 Med: 10.83 Max: 38.48
Current: 2.09
During the past 13 years, Glycorex Transplantation AB's highest Altman Z-Score was 38.48. The lowest was -1.00. And the median was 10.83.
Glycorex Transplantation AB (FRA:O33) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:O33 vs VRTX, REGN, RVMD: Altman Z-Score Comparison
For the Biotechnology subindustry, Glycorex Transplantation AB's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glycorex Transplantation AB Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Glycorex Transplantation AB's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Glycorex Transplantation AB's Altman Z-Score falls into.
Glycorex Transplantation AB Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Glycorex Transplantation AB (FRA:O33) has a Altman Z-Score of 1.40 as of Aug. 05, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Glycorex Transplantation AB and its competitors. This is 87% below median its historical median of 10.83. According to the industry distribution chart, Glycorex Transplantation AB ranks #492 out of 932 companies in the Biotechnology industry, placing it in the top 52.8%.
Is Glycorex Transplantation AB's Altman Z-Score too high?
Glycorex Transplantation AB's current Altman Z-Score of 1.40 is 87% below median its 10-year median of 10.83. The Biotechnology industry median Altman Z-Score is 2.39. Glycorex Transplantation AB's value of 1.40 is 41.3% below this industry median. Based on the distribution chart, Glycorex Transplantation AB ranks #492 out of 932 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Glycorex Transplantation AB has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Glycorex Transplantation AB's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Glycorex Transplantation AB ranks #492 out of 932 companies for Altman Z-Score. This places Glycorex Transplantation AB in the lower half of its industry. The industry median Altman Z-Score is 2.39. Glycorex Transplantation AB's value of 1.40 is 41.3% below this benchmark. While the company's 10-year median is 10.83 vs. the industry median of 2.39, Glycorex Transplantation AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.39, based on 932 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glycorex Transplantation AB's current Altman Z-Score of 1.40 is 41.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Glycorex Transplantation AB and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glycorex Transplantation AB's current Altman Z-Score is 1.40, which is 87% below median its own 10-year median of 10.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glycorex Transplantation AB stock overvalued right now?
Based on GuruFocus' analysis, Glycorex Transplantation AB (FRA:O33) is currently considered Possible Value Trap. The stock's GF Value™ is €0.14, compared to a current price of €0.09 — trading 36.7% below its estimated fair value. The current Altman Z-Score is 1.40, which is 87% below median its 10-year median of 10.83 and 41.3% below the Biotechnology industry median of 2.39. Glycorex Transplantation AB's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Glycorex Transplantation AB (FRA:O33), the current Altman Z-Score is 1.40 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glycorex Transplantation AB (FRA:O33) Overvalued in 2026?
Based on GuruFocus' analysis, Glycorex Transplantation AB stock appears to be undervalued.
The current stock price of €0.09 is trading 36.7% below its estimated GF Value™ of €0.14.
GuruFocus considers Glycorex Transplantation AB to be Possible Value Trap.
Key valuation signals for FRA:O33:
Altman Z-Score: 1.40 (87% below median its 10-year median of 10.83)
GF Value™: €0.14 vs. price of €0.09 (36.7% below fair value)
Industry Position: 41.3% below the Biotechnology median (#492 of 932)
No single metric tells the full story. See the FRA:O33 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glycorex Transplantation AB is a medical technology company. Its main product Glycosorb ABO is used clinically in six continents to facilitate blood group incompatible transplants, especially in kidney transplants from related living donors, but also in transplantation of liver, heart, lung and stem cells. Glycosorb ABO enables grafts regardless of the blood group of donors and recipients. The product is used in extracorporeal blood treatment, that is, a blood treatment that takes place outside the body in the same way as dialysis. Its segment is research, develop, manufacture, market and sell products in the field of organ transplantation or related areas. Geographically it operates in Europe, Australia, Singapore, India, and Other countries with majority of revenue from Europe.
61GF Score
Get the complete analysis for FRA:O33
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O33 has been successfully added to your 
